viewROBO Global

ROBO Global healthcare technology ETF to make NYSE debut

The ROBO Global Healthcare Technology & Innovation ETF consists of 85 constituent companies in nine medical subsectors

Jeremie Capron and Morten Paulson
ROBO Global Head of Research Jeremie Capron (left) with Morten Paulson of CLSA Japan at the NYSE

ROBO Global, the company behind the first benchmark index to track robotics, automation and artificial intelligence, announced Tuesday that it has a new innovative healthcare index.

The company's investment thesis will be rolled into a new exchange traded fund that will debut on the New York Exchange on Tuesday.

The ROBO Global Healthcare Technology & Innovation ETF (NYSE:HTEC) consists of 85 constituent companies in nine medical subsectors. The index will rebalance quarterly and uses a modified factor weighting scheme, meaning certain components affect the index’s value more than others

READ: ROBO Global finds the AI technologies giving HBO's 'Westworld' so much whizbang are not all fiction

The Dallas-based company partnered with Exchange Traded Concepts to create the fund. ETC also helped launch the ROBO Global Robotics & Automation Index ETF (NYSEArca:ROBO) in 2013.

“By and large, the healthcare industry appears to be primed for massive market growth thanks to the implementation of advanced technologies like robotics and AI,” CEO Travis Briggs said. “The healthcare AI market is expected to grow at a compound annual growth rate between 47-50% by 2025, a value of $36 billion.”

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: ROBO Global


Price: 68.21 USD

Market Cap: $1.91 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Delta 9 Cannabis hit top 10 of Globe and Mail's Top Growth companies survey

Delta 9 Cannabis CEO John Arbuthnot joined Steve Darling from Proactive to share news the company finished 7th in the Globe and Mail’s 3rd Annual Top Company growth survey with 448 entrants based on 3-year growth. Delta 9 saw an increase of revenue over 3 years of 5,413 percent. Arbuthnot...

2 hours, 32 minutes ago

2 min read